Development and application of a pathology supported pharmacogenetic test for improved clinical management of South African patients with breast cancer and associated co-morbidities
Year: 2016
Type: dissertation
Study design: Observational Study
Abstract: ENGLISH ABSTRACT: Three major challenges in the field of breast cancer have been identified as research priorities \nfor this study. The first is the need to combine genetic testing of high-risk patients with familial \nbreast cancer with pharmacogenetics to reduce recurrence risk in cancer survivors due to drug \nfailure as a consequence of anti-cancer treatment that does not match the patient’s genotype. \nThe second is the delineation of key pathways through which genes implicated in breast cancer \nand associated co-morbidities can serve as nutritional and drug targets across diagnostic \nboundaries. The third is the discovery of genetic alterations underlying familial breast cancer not \nattributed to mutations in the two major tumour suppressor genes, BRCA1 and BRCA2. \nThe study population consisted of 164 breast cancer patients (60 Coloured/Mixed Ancestry and \n104 Caucasian), of whom 88 patients were selected from a total of 813 individuals who provided \ninformed consent for inclusion of their data in a genomics database resource generated at the \ninterface between the laboratory and routine clinical practice. In addition, DNA samples of 101 \ncancer-free individuals above the age of 65 years were available for clinical validation of \npotentially causative variants in an extended female control group. \nIn the first phase of this study, real-time polymerase chain reaction (PCR) TaqMan© technology \nwas used to confirm the potential value of adding pharmacogenetic testing (CYP2D6 allele 4) to \nstandard immunohistochemistry (IHC)-based breast tumour subtyping complemented by BRCA \nmutation screening and/or microarray gene profiling in eligible patients. In phase two of the \nstudy, common genetic risk factors for cardiovascular disease (CVD) were shown to be \nsignificantly associated with earlier age (10 years on average) of breast cancer onset/diagnosis \n(APOE E4 allele p=0.003; 95% CI: 4-15) and body mass index (BMI) (MTHFR 1298 A>C; \np=0.01; 95% CI: 3-14) in patients stratified according to estrogen receptor (ER) status, after \nadjustment for potential confounders. Age at diagnosis/onset of breast cancer was significantly \nlower in patients with ER-negative versus ER-positive tumours, after adjustment for ethnicity \n(p=0.022), while BMI was significantly higher in patiens with ER-positive compared to ERnegative \ntumours after adjustment for age, ethnicity, and family history of cancer (p=0.035). \nThese findings contributed to the development of an exome pre-screening algorithm (EPA) used \nin part 3 of this study to select three genetically uncharacterized breast cancer patients for \nwhole exome sequencing (WES) performed in comparison with three ethnically concordant \ncancer-free controls. WES followed by variant calling using both the standard human genome \nreference sequence (hg19) and an ethnically concordant major allele reference genome \n(MARS) revealed a more than 20% discrepancy in the number of gene variants identified in the \nsame samples. After exclusion of a large number of false-positives caused by minor alleles in \nhg19, two rare missense mutations (<1%) were identified in a family with ER-positive breast \ncancer: RAD50 R385C and MUC1 Q67E. Three different bioinformatics tools were used to \npredict functionality and both mutations were confirmed by Sanger sequencing and/or real-time \nPCR in the Pathology Research Facility (PRF) laboratory. Neither the RAD50 nor the MUC1 \nmissense mutation were identified in the exomes of an unrelated breast cancer patient with \ntriple-negative breast cancer or three population-matched control individuals. \nThis study led to the development of a pathology-supported genetic testing framework for WES \nbeyond the limitations of single-gene BRCA mutation screening in South African breast cancer \npatients. Our findings support previous WES results indicating that the majority of genetically \nuncharacterised familial breast cancer may be caused by a combination of low-moderate \npenetrance mutations exerting their effect in a high-risk environment reflected by high BMI. \nWES enables identification of genetic risk factors of relevance to both cancer development and \ntailored therapeutic intervention in a single genetic test.
Author: Nicole van der Merwe
Institution: Stellenbosch University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2345225167
